Premiums, deductibles, and cost sharing for various plans vary greatly, the analysts found. At the five largest drug plans, beneficiaries paid anywhere from nothing to $7 for first-tier drugs. Second-tier therapies cost $22–$40; although one plan charged a 28% coinsurance rate and another 25%. With so much variation, it's difficult to make a blanket statement about the impact of cost sharing for beneficiaries, said Sarah Barber, an ACS CAN researcher. How much beneficiaries will shoulder depends on the type of cancer they have, where they live, the mix of drugs they receive, and what plan they have for Part D, she said.